Pneumococcal vaccine recombinant (GlaxoSmithKline)

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NamePneumococcal vaccine recombinant (GlaxoSmithKline)

Drug Alias Name肺炎球菌疫苗重组 - 葛兰素史克Streptococcus pneumoniae recombinant-conjugated vaccineS. pneumoniae adult vaccineGSK-2189242-A2189242-A

ClassificationVaccines > Biological material > Bacterial vaccineVaccines > Application > Prophylactic vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsStreptococcal Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaBelgiumUnited States +[7]

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsStreptococcal Infections

ATC CodeN/A